220578-59-6

Basic information

• Product Name: Gemtuzumab
• Synonyms: Gemtuzumab;Cdp 771;Gemtuzumab ozogamicin;Gemtuzumab ozogamicin [usan];Immunoglobulin G4 (anti-(human cd33 (antigen)) (human-mouse monoclonal hp67.6 gamma4-chain)), disulfide with human-mouse monoclonal hp67 6kappa-chain, dimer, methyl ((1R,4Z,8S,13E)-8-((2-o-(4-(acetylethylamino)-2,4-dideoxy-3-o-methyl-alpha-L-threo-pentopyranosyl)-4,6-dideoxy-4-(((2,6-dideoxy-4-S-(4-((6-deoxy-3-o-methyl-alpha-L-mannopyranosyl)oxy)-3-iodo-5,6-dimethoxy-2-methylbenzoyl)-4-thio-beta-D-ribo-hexopyranosyl)oxy)amino)-beta-D-glucopyranosyl)oxy)-13-(2-((3-((1-(4-(4-amino-4-oxobutoxy)phenyl)ethylidene)hydrazino)-1,1-dimethyl-3-oxopropyl)dithio)ethylidene)-1-hydroxy-11-oxobicyclo(7.3.1);Unii-8gzg754X6m;Way-cma 676
• CAS NO: 220578-59-6
• Molecular Weight: 1209.3983
• Mol File: 220578-59-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.44g/cm³
• Refractive Index: 1.681
• CAS DataBase Reference: Gemtuzumab(CAS DataBase Reference)
• NIST Chemistry Reference: Gemtuzumab(220578-59-6)
• EPA Substance Registry System: Gemtuzumab(220578-59-6)

Safety Data

• Hazardous Substances Data: 220578-59-6(Hazardous Substances Data)

Usage

Description

Gemtuzumab ozogamicin, also known as Mylotarg, is a fusion molecule that serves as an antibody-targeted antineoplastic agent. It is a humanized mouse monoclonal antibody (IgG4) derived from the CD33 antigen, which is a sialic acid-dependent adhesion protein. This protein is expressed on the surface of leukemia blasts and immature normal cells of myelomonocytic origin but not on normal hematopoietic stem cells or nonhematopoietic cells. Gemtuzumab ozogamicin is linked to the cytotoxic antibiotic calicheamicin via a bifunctional linker. When the anti-CD33 antibody binds to its antigen, the complex is internalized, and the calicheamicin derivative is released inside the cell, causing double-strand breaks and cell death.

Uses

Used in Oncology:
Gemtuzumab is used as a treatment for patients with CD33-positive acute myeloid leukemia (AML) in first relapse. It is particularly indicated for adults aged 60 years or older who are not considered candidates for cytotoxic chemotherapy. The drug has demonstrated an acceptable safety profile and has achieved meaningful clinical remission in 32 to 43% of individuals, making it at least as effective as conventional therapy with a more favorable tolerability profile compared to standard chemotherapeutic drugs used to treat AML.
Used in Pharmaceutical Industry:
Gemtuzumab ozogamicin is used as an antibody-targeted antineoplastic agent for the development of novel cancer treatments. Its unique mechanism of action, which involves binding to the CD33 antigen and releasing the calicheamicin derivative inside the cell, has made it a promising candidate for the treatment of acute myeloid leukemia. The drug has received accelerated approval from the FDA and is marketed under the brand name Mylotarg by Wyeth.

Originator

Celltech Group/Wyeth-Ayerst Research (AHP) (US / UK)

target

CD33

InChI:InChI=1/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)